Lead-related nephrotoxicity: A review of the epidemiologic evidence  by Ekong, E.B. et al.
Lead-related nephrotoxicity: A review of the
epidemiologic evidence
EB Ekong1, BG Jaar2,3 and VM Weaver1,3
1Division of Occupational and Environmental Health, Department of Environmental Health Sciences, Johns Hopkins University
Bloomberg School of Public Health, Baltimore, Maryland, USA; 2Department of Epidemiology, Johns Hopkins University Bloomberg
School of Public Health, Baltimore, Maryland, USA and 3Department of Medicine, Johns Hopkins University School of Medicine,
Baltimore, Maryland, USA
Chronic kidney disease (CKD) represents a major global
public health concern. Efforts to prevent and/or slow
progression of CKD are essential. Lead nephropathy,
characterized by chronic tubulointerstitial nephritis, is a
well-known risk of chronic, high-level lead exposure.
However, in recent years, lead exposure has declined
sharply, particularly in developed countries. We reviewed
epidemiologic research in general, occupational, and patient
populations to assess whether lead, at current exposure
levels, still contributes to nephrotoxicity. Other pertinent
topics, such as risk in children, genetic susceptibility, and
coexposure to cadmium, are also considered. The data
reviewed indicate that lead contributes to nephrotoxicity,
even at blood lead levels below 5 lg/dl. This is particularly
true in susceptible populations, such as those with
hypertension (HTN), diabetes, and/or CKD. Low
socioeconomic status is a risk factor for both lead exposure
and diseases that increase susceptibility. Future public health
risk for lead-related nephrotoxicity may be most significant in
those rapidly developing countries where risk factors for
CKD, including obesity and secondary HTN and diabetes
mellitus, are increasing more rapidly than lead exposure is
declining. Global efforts to reduce lead exposure remain
important. Research is also needed to determine whether
specific therapies, such as chelation, are beneficial in
susceptible populations.
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Chronic kidney disease (CKD) represents a major public
health concern. A recent analysis of US National Health
and Nutrition Examination Survey data estimated that
19 million Americans have CKD, which includes end-stage
renal disease and the four stages of renal dysfunction that
precede it.1 Worldwide, the estimated number of end-stage
renal disease patients increased from 886 023 in 1999 to
1 131 594 in 2003.2 Prevalence rates vary and are much
higher in certain groups. In the US, for example, African-
Americans have rates of end-stage renal disease that are four
times higher than those in Caucasians.2 Despite improve-
ments in therapy, mortality remains substantial. Fewer than
40% of patients survive more than 5 years after onset of
dialysis.2 Recent data indicate that obesity is also increasing
globally,3,4 resulting in greater prevalence of diabetes
mellitus and hypertension (HTN),5–8 which are the leading
causes of CKD. Obesity may increase CKD risk by other
pathways as well.9
In this setting, strategies to prevent CKD and/or slow
progression at earlier stages are imperative and will require a
global effort. Exposure to environmental and occupational
nephrotoxicants is not commonly considered in this regard.
However, chronic, high-level lead exposure, that is, blood
lead levels persistently above 70–80 mg/dl, is an established
risk factor for CKD. This has been documented in long-term
follow-up of children in the Queensland, Australia lead
poisoning epidemic,10 mortality studies of lead exposed
workers,11 historical occupational experience,12 and animal
models.13 At this level of exposure, lead is generally the
primary cause of renal pathology, which is characterized by
chronic tubulointerstitial nephritis and diagnosed as lead
nephropathy.14 Fortunately, exposure at these levels is
increasingly rare, particularly in developed countries. The
geometric mean blood lead level in adults declined from
13.1 mg/dl in the National Health and Nutrition Examination
Survey II, conducted between 1976–1980,15 to 1.56 mg/dl in
the most recent survey conducted between 2001 and 2002.16
Similarly, occupational lead exposure in industrialized
countries, although much higher than environmental ex-
posure, is well below historic levels associated with lead
nephropathy.
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In this review, we consider whether current lower levels of
lead exposure continue to contribute to nephrotoxicity.
There are a number of reasons for concern in this regard.
Globally, environmental exposure to lead is ubiquitous. Lead
is stored in bone resulting in ongoing endogenous exposure.
Body burdens of such cumulative toxicants tend to increase
with age as does risk for renal disease from other factors. In
addition, despite the overall decline in exposure, certain
populations, even in developed countries, continue to
experience higher lead exposure.17,18 These include inner
city children and adults of lower socioeconomic status,
particularly African-Americans who, as noted above, also
have a higher prevalence of end-stage renal disease. Occupa-
tional settings of particular concern include small and/or
mobile workplaces, such as radiator repair shops and
construction sites. Children continue to be exposed from
lead paint. Many other sources of lead exposure have been
identified, such as children’s jewelry,19 folk remedies, glazed
pottery, and even candy.20 Recently, attention has focused on
urban water as a continued source of lead exposure.21,22
Internationally, blood lead levels are higher in developing
countries owing to continued use or later phase-out of leaded
gasoline and paint.23,24 Occupational exposure in these
countries is higher as well.
In order to review recent research of relevance for the
question of lead-related nephrotoxicity at current exposure
levels, we have categorized the literature by study popula-
tion as strengths, weaknesses, and conclusions that can be
made are different in each setting. Several lead dose
measures are used in this body of literature. Blood lead is
a short-term measure (half-life of 30 days25) that reflects
exposure from current exogenous sources and the release of
endogenous lead from bone. Bone lead is a cumulative dose
measure that also provides information on potential for
endogenous exposure.25,26 Lead in trabecular bone (com-
monly measured in the patella or calcaneus) is more
bioavailable than lead in cortical bone (measured in the
mid-tibia) and has a shorter half-life (estimated at 1–16
years compared to 10–30 years for cortical bone.25,27
Chelatable lead is thought to represent a bioavailable pool
of lead from blood, soft tissue, and bone. Calcium disodium
ethylenediaminetetraacetic acid (EDTA) has traditionally
been used for chelation; dimercaptosuccinic acid (Succimer)
is a more recent option.
LITERATURE SEARCH STRATEGY
We searched MEDLINE for studies involving the effect of
lead on the kidney in humans using the following terms:
lead and (occupational, environmental, or exposure) and
(kidney, renal or nephrotoxicity). Limits included human
and English language. The time period covered 1 January
1985–31 December 2005 to include the initial general
population studies on the topic. An additional search for
general population studies was conducted using the same
search terms and time period in an Embase search, which
was limited to humans but had no language limits.
Pertinent earlier papers from the investigators’ files were
discussed when relevant. We manually reviewed cited
references from identified articles. Owing to the hetero-
geneous populations studied, small number of publica-
tions in general populations, and the range of renal
outcomes analyzed, no attempt to pool data quantitatively
was made. Therefore, studies were not excluded per se.
However, studies that incorporated stronger designs and
analyzed renal outcomes of known prognostic value were
emphasized.
GENERAL POPULATION STUDIES
We identified 17 publications within the past two decades
that have evaluated the effect of environmental lead exposure
on renal function in adult general populations.17,28–43 In six
publications, early biological effect markers were the only
renal outcome measures analyzed.38–43 Determining the
clinical relevance of these results is difficult owing to the
limited number of prospective studies documenting the
prognostic value of these markers in lead exposed popula-
tions. Therefore, the 11 studies that analyzed clinical renal
outcomes (blood urea nitrogen, serum creatinine, measured
and/or estimated creatinine clearance, and/or estimated
glomerular filtration rate (GFR)) were summarized (Table 1).
These publications included eight populations, primarily in
the US and Europe. Four publications addressed different
time points or lead dose measures in the same longitudinal
study (Normative Aging Study). Statistically significant
associations between higher lead dose and worse renal
function were observed in nine publications (representing
six different populations). Associations between blood lead
and creatinine-based renal outcomes were the most com-
monly reported.17,29–31,33,35,36 Results in longitudinal data
were consistent with those observed cross-sectionally,
although significant associations were limited to susceptible
populations (diabetics and hypertensives) in one study.33
Hypertensives also emerged as a susceptible group in
National Health and Nutrition Examination Survey data.35
Both studies that measured bone lead reported associations
not observed with blood lead, suggesting that assessment of
cumulative lead dose is important in understanding lead-
related nephrotoxicity.32,33 A review of the two studies in
which no significant associations were observed is notable for
the fact that one is limited by small sample size and minimal
statistical analysis.37
Overall, these studies have a number of strengths
including assessment of a range of lead dose measures and
renal outcomes; statistical analysis that adjusted for numer-
ous renal risk factors and, in two, evaluated longitudinal
data;31,33 and generally large sample sizes. The analyses of
National Health and Nutrition Examination Survey data have
the advantage of being representative of the US non-
institutionalized, civilian population.17,35 The general con-
sistency of the results provides important evidence that
lead-related nephrotoxicity remains a public health concern,
particularly in susceptible populations.
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Table 1 | Research on the renal effects of lead exposure in general populationsa
Reference and
study location
Study population;
date; sample size;
% male
Mean (s.d. or range)
Age (years)
Blood lead (lg/dl) Study design
Statistical modeling;
covariates
Adjusted b coefficients (95% CI)
for observed associations
Longitudinal studies
Kim et al.31
Boston, MA, USA
Normative Aging
Study; 1979–1994;
459; 100%
At baseline:
56.9 (37.7–87.5) years
9.9 (6.1) mg/dl
Longitudinal and cross-
sectional analysis of data
from examinations
conducted every 3–5 years;
Exclusionary criteria not
specified
Random effects
Baseline age, time since
initial visit, body mass
index, smoking status,
alcohol ingestion,
education level,
hypertension, and in
longitudinal analysis,
serum creatinine at the
beginning of the follow-
up interval and time
between evaluations
Longitudinal analysis
Log-transformed blood lead and change
in serum creatinine over subsequent
follow-up period in:
All participants (P=0.07)
0.02 (0.004, 0.044)
428 whose peak blood lead was p25 mg/dl
0.027 (0.0, 0.054)
Cross-sectional analysis
Log-transformed blood lead and concurrent
serum creatinine in:
All participants
0.033 (0.009, 0.057)
141 whose peak blood lead was p10 mg/dl
0.06 (0.023, 0.097)
10-fold higher blood lead level associated
with 0.08 (95% CI: 0.02, 0.13) mg/dl higher
concurrent serum creatinine and a 0.05 (95%
CI: 0.01, 0.10) mg/dl greater change in serum
creatinine over the subsequent follow-up
interval in all participants after adjustment
Tsaih et al.33
Boston, MA, USA
Normative Aging
Study;
1991 to B2001;
448; 100%
At baseline:
66.0 (6.6) years;
6.5 (4.2) mg/dl
Longitudinal and cross-
sectional analysis of data
from two evaluations over
a mean 6-year period
Six (n=26) and 26% of
subjects had diabetes and
hypertension, at baseline,
respectively
Tibia and patella lead also
measured
Exclusionary criteria=no
follow-up in 259; serum
creatinine, lead dose, and
key covariates not
statistically different at
baseline between those
with and without follow-up
Multiple linear
regression, interaction
models
Age, age squared, body
mass index, diabetes,
hypertension, smoking
status, alcohol
consumption, analgesic,
and diuretic use, and in
longitudinal analyses,
baseline serum
creatinine and its square
Longitudinal analysis
Baseline lead dose not associated with change
in creatinine in all 448.
0.009 (0.001, 0.019) (for natural
ln-transformed blood lead)
Significant interaction of ln baseline blood
and tibia lead with diabetes in models of
annual change in serum creatinine. For ln
blood lead:
0.076 (0.031, 0.121) in diabetics
0.006 (0.004, 0.016) in non-diabetics
Interaction also noted in hypertensive
participants with tibia lead, although the
diabetics likely present in this group may have
been influential there as well.
Cross-sectional analysis
No significant associations between lead dose
and concurrent serum creatinine at baseline in
all 448; ln-transformed tibia lead associated
with serum creatinine in diabetics.
One of three associations at follow-up
significant: natural ln-transformed blood lead
with concurrent serum creatinine
0.149 (0.041, 0.257)
Cross-sectional studies: Renal outcomes include estimated/measured creatinine clearance and/or estimated GFR
Akesson et al.36
Sweden
Women’s Health in
the Lund Area
Study; 1999–2000;
820; 0%
Medians:
58 (53–64) years
2.2 (1.1–4.6 (5th and
95th %)) mg/dl
Exclusionary criteria=renal
cancer (n=1) and lithium
treatment (n=3)
Multiple linear
regression
Age, body mass index,
diabetes, hypertension,
and regular use of
nephrotoxic drug,
blood, and urinary
cadmium (in separate
models), smoking status
(by stratification)
Blood lead (mg/dl) with GFR (ml/min)
estimated from cystatin C:44 –2.0 (3.2, 0.9)
Blood lead (mg/dl) with estimated creatinine
clearanceb (ml/min): –1.8 (3.0, 0.7)
Muntner et al.35
US
NHANES III;
1988–1994;
Study population
representative
of US non-
institutionalized,
Age reported
categorically
4.21 (0.14) mg/dl
(hypertensives)
3.30 (0.10) mg/dl
(normotensives)
Renal outcomes=elevated
serum creatinine (defined as
X99th percentile of each
race–gender-specific
distribution for participants
aged 20–39 years without
Multiple logistic
regression
Age, race, gender,
diabetes, systolic blood
pressure, smoking
Odds ratios for both renal outcomes increased
by quartile of blood lead among
hypertensives but not normotensives.
Odds ratios for CKD in hypertensives after
adjustment:
Table 1 continued on following page
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Table 1 | Continued
Reference and
study location
Study population;
date; sample size;
% male
Mean (s.d. or range)
Age (years)
Blood lead (lg/dl) Study design
Statistical modeling;
covariates
Adjusted b coefficients (95% CI)
for observed associations
civilian population;
15 211 (4813
hypertensives); 48%
hypertension or diabetes)
and CKD (defined as
estimated GFRco60 ml/
min/1.73 m2)
Exclusionary criteria not
specified; data from 13 141
of 18 825 adults used in final
models
status, history of
cardiovascular disease,
body mass index,
alcohol consumption,
household income,
education level, marital
status, and health
insurance
Blood lead % Odds ratio
(95% CI)
Quartile 1 (0.7–2.4) 6.1 1.00
Quartile 2 (2.5–3.8) 10.4 1.44 (1.00, 2.09)
Quartile 3 (3.9–5.9) 10.8 1.85 (1.32, 2.59)
Quartile 4 (6.0–56.0) 14.1 2.60 (1.52, 4.45)
Po0.001 for w2 test for trend
Twofold higher blood lead associated with
odds ratio for CKD of 1.38 (95% CI: 1.15, 1.66)
in hypertensives after adjustment
In normotensives, higher blood lead was
associated with a higher prevalence of CKD in
diabetics
Muntner et al.17
US
NHANES 1999–2002;
9961; gender not
reported
Age not reported
Geometric mean
(95% CI)
1.64 (1.59, 1.68) mg/dl
CKD (defined as estimated
GFRco60 ml/min/1.73 m2)
Exclusionary criteria not
specified
Multiple logistic
regression
Age, race/ethnicity,
gender, diabetes,
smoking status, alcohol,
body mass index,
education, and health
insurance
Odds ratios for CKD in all increased by quartile
of blood lead, significant w2 test for trend
Payton et al.30
Boston, MA, USA
Normative Aging
Study; 1988–1991;
744; 100%
64.0 (7.4) years;
8.1 (3.9) mg/dl
Exclusionary
criteria=missing data
present in 251
Multiple linear
regression
Age, body mass index,
analgesic & diuretic use,
alcohol consumption,
smoking status, systolic/
diastolic blood pressure
Log transformed (ln) blood lead with ln 24-h
measured creatinine clearance
0.04 (0.079, 0.001)
After adjustment, a 10 mg/dl higher ln blood
lead was associated with a 10.4 ml/min lower
ln creatinine clearance. A 10-fold increase in
blood lead associated with 9% decrease in
creatinine clearance (as noted by Kim et al.31)
Borderline significant (Po0.1) associations
between ln blood lead and both serum
creatinine (b=0.027) and ln estimated
creatinine clearanceb (b=0.022)
Staessen et al.29
Belgium
Cadmibel study;
1985–1989; general
Belgian population
in four cadmium
polluted and
unpolluted areas;
1981; 48.7%
48 (16) years
Geometric mean
Males: 11.4
(2.3–72.5) mg/dl
Females: 7.5
(1.7–60.3) mg/dl
Exclusionary
criteria=missing data
present in 302; potentially
inaccurate 24 h urine
collections in 44
Multiple linear
regression
Age, age squared,
gender (by stratifying),
body mass index, blood
pressure, ferritin level,
smoking status, alcohol
ingestion, rural vs urban
residence, analgesic,
and diuretic use, blood,
and urinary cadmium,
diabetes, occupational
exposure to heavy
metals, and gamma
glutamyl transpeptidase
Log transformed blood lead with 24 h
measured creatinine clearance
9.5 (18.1, 0.9) in males
12.6 (20.3, 5.0) in females
10-fold higher blood lead associated with
10 and 13 ml/min lower measured creatinine
clearance in men and women, respectively
Log-transformed blood lead also negatively
associated with estimated creatinine
clearanceb but not significantly associated
with serum creatinine
Wu et al.32
Boston, MA, USA
Normative Aging
Study, 1991–1995
709; 100%
67.0 (7.4) years
6.2 (4.1) mg/dl
Tibia and patella lead
also measured
Exclusionary criteria
not specified
Multiple linear
regression
Age, body mass index,
hypertension, smoking
status, alcohol
ingestion, analgesic
medication use
Significant negative association between
patella lead and estimated creatinine
clearanceb: b=0.069; P=0.02 (neither s.e.
nor CI provided)
Borderline significant (P=0.08) negative
association between tibia lead and creatinine
clearance. No lead measure was significantly
associated with serum creatinine; no blood
lead associations were significant
Cross-sectional studies: Other clinical renal outcomes
De Burbure et al.34
France
399 adults who
lived X8 years near
two nonferrous
smelters; 50% males
Means ranged from 34.6
(8.9) years (exposed
males) to 35.9 (9.6) years
(exposed females)
Exclusionary criteria
included pregnancy, cancer,
diabetes, kidney disease,
occupational smelter
Multiple linear
regression
Age, sex, body mass
No significant difference in mean serum
creatinine between exposed and unexposed
groups. After adjustment for covariates, log-
transformed blood lead not significantly
Table 1 continued on following page
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OCCUPATIONAL POPULATION STUDIES
Research on renal outcomes from occupational lead exposure
is categorized by reported results (Table 2). Compared to the
work described above in general populations, this body of
literature is larger, however, the results are less consistent.
This is puzzling as most dose–response relations are linear.
Biologically, lead dose consistent with occupational exposure
(i.e., blood lead levels between 20 and 50 mg/dl) should be
nephrotoxic if lower (o10 mg/dl) and higher (480 mg/dl)
doses are. A number of factors may be involved in this
seeming paradox. Some are unique to the occupational
literature. These studies generally have small sample sizes,
resulting in less power to detect significant differences. Most
are cross-sectional studies of currently employed workers, a
group that is well known to be healthier than the general
population (the healthy worker effect). Lead workers who are
followed in a medical surveillance program (a common
practice) are often removed from exposure if renal function
decline is observed. This may result in removal from the
workplace, yet few studies have included former workers. In
many studies, exclusionary criteria for a range of diseases,
such as HTN and diabetes, were applied. The number of
workers subsequently excluded was not always reported,
making it difficult to determine if the healthy worker effect
was substantially increased. Statistical analyses were more
limited than in general population studies. Analyses limited
to comparisons of crude mean outcomes between exposed
and control workers are problematic, when lead levels in the
latter group are in the range associated with adverse renal
outcomes in the general population. Limited lead exposure
assessment may also be a factor, as few studies have included
cumulative measures of lead dose and blood lead varies more
owing to external exposure in the occupational setting. Other
limitations that are pertinent for research on the adverse
renal effects of lead exposure in any population include
insensitivity of the clinical renal outcomes and the lack of
uniformly accepted early markers of renal damage in lead
exposure. As discussed below, coexposure to environmental
cadmium may also account for differences in reported
associations between studies, particularly for N-acetyl-b-D-
glucosaminidase (NAG). In general, these limitations result
in bias towards the null meaning that actual associations are
obscured.
Finally, one factor that has received relatively little
attention to date involves the paradoxical inverse associations
observed in some studies (Table 2; Category 4). These
unexpected associations have been reported with blood,
tibia, and dimercaptosuccinic acid-chelatable lead in the
Table 1 | Continued
Reference and
study location
Study population;
date; sample size;
% male
Mean (s.d. or range)
Age (years)
Blood lead (lg/dl) Study design
Statistical modeling;
covariates
Adjusted b coefficients (95% CI)
for observed associations
201 age- and
gender-matched
controls
Date not provided
(Note – only results
in adults presented
herein)
Geometric means
ranged from 4.2
(0.2) mg/dl (control
females) to 7.1 (0.18) mg/
dl (control males)
exposure, recent dental
work, and missing data.
Numbers excluded not
stated, however, serum
creatinine data reported
in 479 of original 600
index, area of residence,
smoking, alcohol
ingestion, log urine
mercury, log blood
cadmium and urinary
creatinine
associated with serum creatinine (data not
presented in publication).
Mortada et al.37
Egypt
Not applicable –
details of
population
recruitment not
provided; date not
provided
68; 100%
30 (25–35) years
(smokers)
31.8 (25–38) years
(non-smokers)
14.4 (3.4) mg/dl
(smokers)
10.2 (3.1) mg/dl
(non-smokers)
Also measured cadmium,
and mercury in blood and
all three metals in urine,
hair, and nails.
Exclusionary
criteria=occupational
exposure to any of the three
metals, dental amalgams,
drug intake, diabetes,
hypertension, and hepatic,
renal or urological disease.
Smokers and non-smokers
matched on socioeconomic
status.
t-test for independent
samples; Spearman
correlation
No significant difference in serum creatinine
or BUN by smoking status (blood lead levels
significantly higher in smokers as compared to
non-smokers). No significant correlations of
any of the four lead measures with renal
outcomes (only assessed in 35 smokers; data
not presented in publication)
Pocock et al.28
Britain
British Regional
Heart Study; year
not provided;
7364; 100%
Mean not reported,
range 40–59 years
Mean blood lead not
reported
Exclusionary criteria not
specified
Correlation; analysis of
covariance adjusting for
alcohol
Correlations of blood lead with log
transformed serum creatinine, urate, and log
urea=0.00, +0.1, 0.08 (unadjusted data)
(Po0.001 for urate and urea)
Partial correlations for urate and urea after
adjustment for alcohol=+0.06 and 0.05
(P-values not reported)
BUN, blood urea nitrogen; CI, confidence interval; CKD, chronic kidney disease; GFR, glomerular filtration rate; NHANES, National Health and Nutrition Examination Survey.
aStudies in adult general populations published in the last 25 years in which relations between lead dose and clinical renal outcomes (BUN, serum creatinine, measured or
estimated creatinine clearance, or estimated GFR) were analyzed.
bCreatinine clearance estimated using the Cockcroft–Gault equation.45
cGFR estimated by the abbreviated Modification of Diet in Renal Disease (MDRD) equation.46
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occupational setting and with blood lead in a recent study of
environmentally exposed children.87 Higher mean creatinine
clearance compared to controls was also observed in one
study of adults who were previously lead poisoned as
children.88 Although observed renal function was not
consistently in a supranormal range, these associations may
indicate a lead-related hyperfiltration process. Data from lead
workers in South Korea suggest a temporal pattern that is
consistent with hyperfiltration.47 Inverse associations (i.e.,
higher lead dose associated with lower serum creatinine)
were noted in younger workers; however, the opposite was
observed in older workers (i.e., higher lead dose associated
with higher serum creatinine). Two longitudinal studies in
rats are critical to our understanding of this process in lead
exposure. High exposure animals had mean blood lead levels
ofB50, 90 and 125 mg/dl at 1, 3, and 6 months, respectively,
at which point lead exposure was reduced and levels declined
to B60 mg/dl at 12 months.13 Lower exposure resulted in
mean blood lead levels between B20 and 30 mg/dl through-
out.89 Compared to controls, mean GFR (measured with
125I-iothalamate clearance) was significantly higher at 1 month
in the lower exposure animals and in both groups at 3 months.
In the high exposure rodents, a positive association between
blood lead and GFR was observed in the first 6 months;
however, tubulointerstitial fibrosis became apparent at 6
months and GFR was decreased compared to controls at 12
months. Interestingly, despite a similar degree of hyperfiltra-
tion initially (and an earlier onset), subsequent renal damage
was much less severe in the lower exposed animals.
Whether this process contributes to pathology in human
lead exposure remains unclear and will require longitudinal
studies. Regardless, significant associations could be obscured
if opposite direction associations are present in different
segments of the study population and interaction models to
address this are not performed. This is a valid concern as the
factors involved in these inverse associations in lead exposed
populations are not well defined at present.
PATIENT POPULATION STUDIES
Studies in various patient populations have also contributed
to the body of knowledge concerning the adverse renal
impact of lead. Patients with CKD, gout, and/or HTN have
been the focus of this work as risk for these diseases is
increased with high-level lead exposure, particularly when
two or more coexist in the same patient. Early research
focused on lead nephropathy and body burdens were high
(4600 to 650 mg lead excreted in 72 h following chelation
with EDTA).90,91 More recent work has involved patients
with earlier stages of CKD and much lower lead body
burdens, thus addressing the issue of low-level lead as a
cofactor with other renal risk factors in susceptible popula-
tions. This work has been published by Lin and co-workers in
Taiwan; a discussion of two recent studies serves to illustrate
the current state of this research and the different approaches
they use to study this issue. The first approach involves
prospective study of susceptible patient populations to
determine if renal function decline is greater in participants
with higher baseline chelatable lead body burdens. Yu et al.92
followed 121 CKD patients over a 4-year period. Eligibility
criteria included stable renal function (serum creatinine
from 1.5 to 3.9 mg/dl), well-controlled blood pressure,
cholesterol and daily protein intake, and EDTA-chelatable
lead o600 mg/72 h. Sixty-three patients had ‘high-normal’
EDTA-chelatable lead levels (X80 but o600 mg/72 h);
Table 2 | Research on the renal effects of occupational lead exposurea
Significant results Details and examples References
Mean difference in one or more measures of clinical renal
functionb between lead workers and control group and/or
positive association(s) between higher lead dose and worse
clinical renal function
Traditional pattern of lead-related nephrotoxicity. Mean
serum creatinine higher in exposed compared to control
workers. Higher blood or bone lead associated with higher
serum creatinine in all workers.
47–57
Mean difference or association for renal biomarkersc; clinical
outcomes not assessed
Relatively recent approach to lead-related nephrotoxicity to
address issue of insensitivity of clinical renal measures.
Higher blood lead associated with higher RBP
58–66
Significant results for renal biomarkers but not clinical
outcomes
Higher blood lead associated with higher RBP but not serum
creatinine
67–78
Paradoxical associations with higher mean creatinine
clearance in the lead exposed group and/or inverse
associations between higher lead dose and worse clinical
renal function
May indicate lead-related hyperfiltration. Higher lead dose
associated with lower BUN and serum creatinine and/or
higher creatinine clearance
47,57,79,80,81
Noned 82–86
BUN, blood urea nitrogen; RBP, retinol-binding protein.
aPublished between 1985–2005, adult populations.
bClinical renal function defined as BUN, serum creatinine, estimated and/or measured creatinine clearances, and/or estimated GFR.
cRenal biomarkers examples include N-acetyl-b-D-glucosaminidase, RBP, b2 microglobulin, and a1-microglobulin.
dInterestingly, one of these studies85 included two workers with high lead dose and lower creatinine clearance who had biopsy evidence of chronic interstitial nephritis, thus a
pattern consistent with lead nephropathy. In another, the association was no longer significant after the removal of two participants with abnormal renal function that appear
to be outliers.86
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58 patients had ‘low-normal’ EDTA-chelatable lead levels
(o80 mg lead/72 h). Mean blood lead was higher in the
former group (4.9 vs 3.4 mg/dl). The groups were similar in
most other baseline risk factors. However, borderline
statistically significant (Po0.1) differences were present
(older age and chronic glomerulonephritis more prevalent
in the ‘high-normal’ lead group chronic interstitial nephritis
and hypertensive nephropathy less prevalent). Fifteen
patients in the ‘high-normal’ chelatable lead group reached
the primary end point (doubling of serum creatinine or need
for hemodialysis) compared to only two in the ‘low-normal’
group (P¼ 0.001).
Associations between baseline chelatable or blood lead
levels and change in GFR were modeled separately using
generalized estimating equations. Based on these models,
10 mg/72 h higher chelatable lead and 1 mg/dl higher blood
lead were associated with a reduction in GFR of 1.3 and
4.0 ml/min/1.73 m2, respectively, during the 4-year study
period. Given the lead dose ranges in this study, this is a
clinically relevant association.
The second approach used by Lin et al., involves
randomized EDTA chelation trials to determine if this
therapy changes the rate of renal function decline. Chelation
in lead exposure is controversial owing to the potential for it
to be used in lieu of exposure reduction. In addition, cases of
acute tubular necrosis were reported following early clinical
use of EDTA that involved very large doses.93 However,
adverse renal effects have not been observed in subsequent
work using lower doses.91,93 In their largest chelation trial to
date, Lin et al.94 randomized 64 patients whose EDTA-
chelatable lead levels were 80–600 mg/72 h; half received
weekly chelation with 1 g EDTA intravenously for up to 3
months (mean 5 weeks) and half received a weekly placebo
infusion for 5 weeks. Renal risk factors were similar in the
two groups. Mean blood lead levels were 6.1 and 5.9 mg/dl in
treated and control groups, respectively. In the subsequent 24
months, chelation was repeated in 19 (59%) participants
owing to increases in serum creatinine in association with
rebound increases in chelatable lead levels. Each received one
additional chelation series (mean of four weekly infusions), a
mean of 13.7 months after the first chelation period. At the
end of the 2-year study period, mean estimated GFR
increased by 2.1 ml/min/1.73 m2 in the chelated group
compared to a decline of 6.0 ml/min/1.73 m2 in the controls
(Po0.01). Benefits from chelation have also been observed in
rodent models of lead-related nephrotoxicity.95–97 This did
not appear to occur via reversal of structural damage;97
improved hemodynamics from reduction of reactive oxidant
species may be a mechanism.98 It is also important to note
that chelation may have a direct beneficial effect on kidney
function, irregardless of lead exposure. Dimercaptosuccinic
acid has been reported to prevent renal damage when
coadministered during induction of nephrosclerosis in a
non-lead-exposed rat model.98
The unique body of work by Lin et al., (which also
includes work in patient populations with gout and HTN not
discussed herein) has numerous strengths including pros-
pective study design, randomization, lead dose assessment
that includes bioavailable body burden, longitudinal statis-
tical analysis, and control for multiple renal risk factors.
However, to date, this work has been performed in small
groups at one clinical center and thus the generalizability of
the results to broader populations is unknown. In addition,
the observed effect of lead on decline in GFR has been
variable. In an earlier study of 202 patients, an increase of
10 mg/72 h in baseline EDTA-chelatable lead was associated
with a decline in GFR of 0.03 ml/min/1.73 m2 over a 2-year
observation period.94 When adjusted for the shorter follow-
up period, this effect, although statistically significant
(Po0.001), is 20-fold lower than in the most recent
work discussed above.92 Small sample sizes and differences
in renal diagnoses between groups may be factors in this
variability.
Although preliminary, this line of research could yield
important public health benefits if confirmed in large
populations (and shown not to worsen cognition). This
would indicate that lead body burden contributes to
worsening renal function in populations with CKD from a
range of causes at much lower levels than previously
recognized. Therapeutic options would be available for
high-risk patients, who, despite reductions in lead exposure,
still experience lead-related nephrotoxicity.
ADDITIONAL CONSIDERATIONS
A number of additional issues may be relevant in assessing
the adverse renal impact of lead exposure. However, data are
currently too limited to merit in depth discussion. Such areas
include the potential for lead-related nephrotoxicity in
children, genetic susceptibility, and coexposures, of which
cadmium is the most important. Lead-poisoned children
who are not chelated are at increased risk for nephropathy as
young adults.10 Recent work in children exposed at lower
levels has generally relied on renal biomarkers for outcome
assessment. As discussed above, few prospective studies
documenting the prognostic value of these markers in lead
exposure have been published. Further, some data suggest
that renal biomarker levels may decrease post-puberty,99 so
prospective biomarker studies specifically in lead exposed
children will be needed to interpret the existing literature.
However, two recent publications deserve comment.
A positive association between blood lead and serum cystatin
C was observed in 200 Belgian adolescents.100 In 600
European children, higher blood lead was associated with
lower serum creatinine and cystatin C,87 in models that
adjusted for age, gender, body mass index, and either blood
or urine cadmium (A. Bernard, e-mail communication).
Prospective studies of renal function in lead-exposed children
are needed to understand the clinical significance of these
findings.
Research in the past two decades suggests that certain
genetic polymorphisms affect lead toxicokinetics (i.e., modify
the relation between lead exposure and internal dose).
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The gene that encodes for d-aminolevulinic acid dehydratase
has received most attention in this regard to date. Overall,
current data suggest that tighter binding of lead by the
isoenzymes of the variant d-aminolevulinic acid dehydratase2
allele leads to higher blood lead levels and decreased lead
sequestration in bone.101,79,102 Data to determine whether the
d-aminolevulinic acid dehydratase polymorphism confers
additional toxicodynamic risk for the kidney are still quite
limited, but are suggestive of an increased risk in lead-
exposed populations with the variant allele.32,79,102–104
Finally, exposure to other environmental nephrotoxicants
may affect risk. Cadmium is likely to be the most important
in this regard as this metal has many similarities to lead. It is
also a cumulative toxicant that is stored long term in the
body. Environmental cadmium exposure in the US occurs
primarily through food and smoking.105 The existing data
indicate that cadmium exposure, at levels common in the US,
confounds associations between lead exposure and at least
one renal outcome, NAG. Studies have reported higher mean
NAG in lead workers compared to controls; however, NAG
was correlated with urinary cadmium (CdU; a cumulative
measure of exposure) rather than lead dose.80,67 CdU was
associated with the NAG-B isoenzyme (released with break-
down of proximal tubular cells) even at CdU levels o2mg/g
creatinine.106 In Korean lead workers, both CdU and tibia
lead were positively associated with NAG47. However, a
0.5 mg/g creatinine increase in cadmium had the same effect
on NAG as a 66.9 mg lead/g bone mineral. The fact that mean
CdU was 1.1 mg/g creatinine, indicating environmental rather
than occupational exposure, again illustrates the impact of
cadmium on NAG.
Lower level cadmium exposure may also confound or
modify relations between lead exposure and clinical renal
outcomes, although the data are too limited to draw firm
conclusions. Occupational cadmium exposure increases the
risk for clinical renal dysfunction,107,108 as does high-level
environmental exposure.109,110 However, most recent studies
of lower level cadmium exposure are cross-sectional and have
assessed renal biomarkers, rather than clinical renal out-
comes.43,111–113 Two recent exceptions include a report of
increased renal dialysis and transplantation rates in residents
of cadmium-polluted areas in Sweden114 and associations of
higher blood lead and blood and CdU with lower estimated
creatinine clearance and GFR in Swedish women.36 However,
as noted above, higher blood lead was associated with lower
creatinine clearance in the Cadmibel study whereas urinary
and blood cadmium were not.29 Additional studies assessing
both lead and cadmium are needed.
CONCLUSIONS
The research reviewed herein utilized a variety of study
approaches in different populations. Overall, these diverse
lines of evidence indicate that lead exposure, at much lower
levels than those causing lead nephropathy, acts as a cofactor
with more established renal risk factors to increase the risk
for CKD and the rate of progression. Adverse renal effects
have been reported at mean blood lead levels o5 mg/dl.
Cumulative lead dose was also associated with worse renal
function. The data available to date are not sufficient to
determine whether current blood lead level or cumulative
exposure with higher past blood lead levels is the more
important determinant of nephrotoxicity. However, Kim
et al.31 noted associations in participants whose peak blood
lead levels, dating back to 1979, werep10 mg/dl. Populations
with diabetes, HTN, and/or CKD appear to be at greater risk
for adverse renal effects from lead. Moreover, recent research
suggests that the adverse impact of lead on renal function
decline in CKD from a range of causes may be reduced with
chelation, even at lead body burdens previously considered
normal. Although preliminary, this line of research deserves
further study as it could yield important public health
benefits if confirmed in large populations.
Residual confounding is unlikely to explain associations
between lead exposure and renal function. Muntner et al.35
observed that the odds ratios for both renal outcomes
assessed in hypertensives, initially adjusted for age, race, and
gender, actually increased slightly following additional
adjustment for a range of covariates including diabetes,
blood pressure, smoking, cardiovascular disease, body mass
index, alcohol, and socioeconomic status indicators. Further-
more, most studies adjusted for blood pressure, which is
likely to be in the causal pathway and thus may result in an
underestimate of effect. Reverse causality, which attributes
increased lead dose in general population studies to reduced
lead excretion as a consequence of renal insufficiency, is also
not likely to be a major explanatory factor. Longitudinal data
indicate that lead dose at baseline is associated with
subsequent decline in renal function. Furthermore, associa-
tions in the Normative Aging Study population occurred over
the entire serum creatinine range,31 and persisted when data
from participants with serum creatinine 41.5 mg/dl were
removed.33 The impact of publication bias is always difficult
to assess. A type of publication bias is present in the reviewed
studies that reported no significant associations but did not
show the data. In addition, at least one cadmium study
appears to include unpublished longitudinal lead data.115
However, no other evidence of unpublished data on
associations between lead dose and renal function in general
populations was identified through the MEDLINE and
Embase search strategies used or in population descriptions
and references of reviewed papers.
Inverse associations between higher lead dose and worse
renal function may be mediated through a hyperfiltration
mechanism. Although potentially of mechanistic importance,
a more immediate concern is the fact that, if interaction is
not specifically explored in data analysis, risk may be
underestimated. The potential for such underestimation in
lead workers, along with new knowledge regarding suscep-
tible populations, indicates that lead exposure in workers
must be controlled not simply to reduce risk for lead
nephropathy but also to minimize steeper renal function
decline with aging as other cofactors develop. Monitoring of
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cumulative lead dose may be important in this effort. Given
these limitations, current permissible exposure levels116,117
may not be as protective for lead workers as previously
thought. Finally, there are a number of data gaps, in terms of
effects in children, genetic susceptiblity factors, and co-
exposures, which require further study.
Globally, despite substantial reductions in lead exposure
overall, two risk groups for lead-related nephrotoxicity
remain: (1) those with higher exposure levels still common
in developing countries and in minority populations in
developed countries and (2) those with other renal risk
factors. From a public health perspective, certain groups,
such as those of lower socioeconomic status, are at highest
risk as they have higher lead exposure and prevalence of
diseases that increase susceptibility. Ultimately, the global
public health impact may be most significant in developing
countries where obesity, and secondary HTN and diabetes
mellitus, are increasing more rapidly than lead exposure is
declining. Continued global efforts to reduce lead exposure
are obviously important; technology transfer is critical to
reduce associated costs. Given the increasing prevalence of
renal disease, research to better delineate the contribution
made by lead exposure and to determine whether chelation is
beneficial is also needed.
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